Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacogenetics of Gemcitabine: Study of the Impact of Genetic Polymorphism of Cytidine Deaminase (CDA) on Toxicity in Resected Pancreatic Adenocarcinomas

NCT01416662 is registered in ClinicalTrials.gov with Federation Francophone de Cancerologie Digestive as lead sponsor.

NCT NCT01416662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01416662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacogenetics of Gemcitabine: Study of the Impact of Genetic Polymorphism of Cytidine Deaminase (CDA) on Toxicity in Resected Pancreatic Adenocarcinomas
Lead sponsor
Federation Francophone de Cancerologie Digestive
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2011
Completion date
September 30, 2015
Enrollment
120 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer